Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

An individual patient data meta-analysis of 2,017 patients from 19 studies has found a high risk of recurrence following treatment of P. vivax malaria with artemether-lumefantrine (AL) and dihydroartemisinin-piperaquine (DP) unless they are co-administered with primaquine. The research supports recommendations that these artemisinin-based combination therapies (ACT) should be combined with primaquine.

Researcher collecting data © Picture: UNICEF/Iman Morooka

Similar stories

Professor Sir Nicholas White obituary in The Times: brilliant clinical scientist

Professor Sir Nicholas White was a pioneering tropical medicine specialist whose work transformed malaria treatment worldwide, as written in The Times. He championed artemisinin-based combination therapies and intravenous artesunate, saving millions of lives. As head of MORU, he built influential research networks across Asia and Africa, publishing over 1,300 papers and shaping global policy. Knighted and widely honoured, he remained active in research until his death in 2026, aged 74.